ALPHA PROLIPSIS

What ALPHA PROLIPSIS does

Alpha Prolipsis is a privately held Greek network of diagnostic centers and medical laboratories operating 6 branches across the Athens metropolitan area (Dafni, Psychiko, Glyfada, Gkizi, Pallini, Chaidari). The company provides a broad portfolio of diagnostic services spanning cytology, hematology, immunology, biochemistry, hormonal, molecular, allergological, and ultrasound imaging, with a strong focus on women's health including cervical cancer screening, HPV-DNA testing, prenatal testing, and breast/thyroid cytology. Its flagship offering is the AI-powered Pap test built on the Hologic Genius Digital Diagnostics System, which it deploys as the first and only reference laboratory in Greece, combining ThinPrep liquid-based cytology with FDA-certified deep learning algorithms that scan thousands of cells and flag anomalies for cytologist review.

The company earns revenue through three principal channels: direct-pay patient fees for diagnostic tests and bundled health packages (€50 for AI Pap test, €200 for FNA with AI), reimbursement from the National Organization for Health Care Services (EOPYY) under contracted-provider status, and participation in the government-run Program Doxiadis national cervical cancer screening program that provides free Pap and HPV-DNA testing to women aged 21–65. Operations are accredited under ELOT EN ISO 15189:2012 and comply with Joint Commission International standards, with results delivered within 24 hours via the PROLIPSISNET online platform. The company collaborates with PROLIPSISNET polyclinics for tissue and cell diagnostic services to referring physicians and clinics.

Customer concentration is heavily weighted toward public payers and government health programs, with EOPYY contracts and Program Doxiadis representing structural revenue anchors alongside individual private-pay patients and physician referrals. The technology stack is differentiated by Hologic's FDA-certified AI system, but the company does not build its own AI models — it operates as a sophisticated channel partner and clinical reference site. Geographic reach is limited to the Attica region, and headcount is reported as 9, which raises questions about operating leverage at the branch level. Strategic momentum is evident in the 2025–2026 launch of new AI-enabled products (Digital Pap Test, FNA with AI, Urine Cytology with AI), expanding AI cytology beyond cervical screening into urological and thyroid diagnostics.

Name

ALPHA PROLIPSIS

Legal name

Alpha Prolipsis

Website

https://alphaprolipsis.gr

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Alpha Prolipsis is a Greek network of 6 diagnostic centers in Athens offering AI-powered cytology (Hologic Genius Digital Diagnostics System), molecular, hematological, and imaging services to patients, referring physicians, and EOPYY-insured and government-screening-program beneficiaries.

Ownership category

akta.pro rank

Product category

Diagnostic Medical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Diagnostic laboratory services
• Medical cytology testing
• AI cancer screening
• Molecular diagnostics
• Preventive health screening

Headquarters

HQ city

Dafni (Δάφνη)

HQ country

Greece

HQ region

Europe

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Laboratory Services: Fees charged for cytological, hematological, immunological, biochemical, hormonal, molecular biology, and other medical laboratory tests and examinations performed at their diagnostic center network.
2. National Screening Program (Program Doxiadis): Participation in the national 'Doxiadis' program for cervical cancer prevention provides government-funded free examinations (Test Pap and HPV-DNA test) for women aged 21-65, with costs covered by public health insurance.
3. Health Insurance (EOPYY) Contracts: As a contracted provider with the National Organization for Health Care Services (EOPYY), the company receives reimbursement for covered diagnostic services rendered to insured patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Alpha Prolipsis operates a network of diagnostic medical centers in Athens delivering cytology, AI-assisted cancer screening, and a broad menu of hematological, immunological, biochemical, hormonal, molecular, allergological, and ultrasound-based diagnostic tests. It is the first Greek laboratory to deploy the FDA-certified Hologic Genius Digital Diagnostics System for AI-powered ThinPrep Pap testing, urine cytology, and fine needle aspiration cytology, and is contracted with EOPYY and the national Doxiadis screening program.

Product overview

Alpha Prolipsis is a network of diagnostic medical laboratories and polyclinics in Athens, Greece. The core offering centers on the Hologic Genius Digital Diagnostics System, which provides AI-powered liquid-based cytology (ThinPrep) for cervical cancer screening and other cytological tests. The portfolio includes AI-enhanced Pap tests, urine cytology, and FNA (Fine Needle Aspiration) for thyroid, breast, and other tissues. Supporting services span hematological, immunological, biochemical, hormonal, molecular (including HPV-DNA PCR and STD testing), allergological tests, ultrasound imaging (TRIPLEX, elastography), and prenatal testing. Results are delivered via the PROLIPSISNET online platform. The network operates 6 locations and is contracted with the Greek national health insurance provider (EOPYY).

Differentiator

Problem solved

Functional benefit

Products and services

• ThinPrep Pap Test with AI (Hologic Genius)

Quantifiable outcome

• Doubles cytologist productivity: up to 200 slides per day vs. 100 previously.
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Hologic Inc.coreTechnology or IntegrationALPHA PROLIPSIS is the first and only laboratory in Greece to implement the Hologic Genius Digital Diagnostics System, an FDA-certified AI-powered digital cytology platform. This partnership enables AI-assisted screening for cervical and other cancers using deep learning algorithms and 14-level focal scanning technology.
• PROLIPSISNETcoreStrategic or Co-development PartnerALPHA PROLIPSIS and PROLIPSISNET are co-located and collaborating networks. PROLIPSISNET private diagnostic laboratories and polyclinics are among the most innovative in Greece, fully modernized with precision, latest-generation equipment. They serve doctors and clinics with complete tissue and cell diagnostic analysis.
• EOPYY (National Organization for Health Care Services)coreOthersThe ALPHA PROLIPSIS network is contracted with EOPYY (National Organization for Health Care Services), allowing insured patients to receive covered diagnostic services with reimbursement through the national health insurance system.
• Program Doxiadis (National Cervical Cancer Prevention Program)coreOthersALPHA PROLIPSIS participates in the national 'Doxiadis' cervical cancer prevention program (Program 'Spiry Doxiadi' - Public Health Prevention Program), offering free Pap test and HPV-DNA testing for women aged 21-65 with AMKA, covering both insured and uninsured individuals.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sonic Healthcare: Global diagnostics operator with extensive network of laboratories across Australia, Europe, and the U.S. Comparable as a multi-country reference-lab chain offering cytology, histopathology, and routine diagnostics.
• Hologic: Global medical technology company that owns the Genius Digital Diagnostics System deployed by Alpha Prolipsis. Comparable as the platform licensor whose AI cytology roadmap directly determines Alpha Prolipsis's technology trajectory.
• Quest Diagnostics: Large U.S. reference laboratory network offering routine and advanced diagnostics including AI-assisted cytology workflows. Comparable as a broad incumbent reference lab with similar technology adoption patterns and women's health focus.
• Unilabs: European diagnostics group with extensive laboratory and sampling center networks across multiple geographies. Comparable as a pan-European reference-lab operator with overlapping clinical diagnostics and women's health offerings.
• LabCorp: Major U.S. clinical laboratory network providing routine and specialty diagnostics including cytology and women's health. Comparable as a large incumbent reference lab with overlapping test menu and referral-based model.
• Synlab: Pan-European medical diagnostics services provider operating hundreds of laboratories across multiple countries. Comparable as a large-scale ambulatory diagnostic chain with overlapping routine and specialty testing menus.

Direct peers

• Diagnostiki: Greek private diagnostic laboratory group with multiple Athens branches offering cytology, hematology, and molecular diagnostics. Closely comparable as a domestic cytology and routine lab competitor with similar EOPYY contracting.
• PROLIPSISNET: Co-located partner and affiliated diagnostic network serving doctors and clinics with tissue and cell analysis. Highly comparable as a Greek diagnostic platform with overlapping cytology and referral workflows.
• Biomedicine: One of Greece's largest diagnostic laboratory networks offering cytology, molecular, and routine testing with multi-branch coverage in Athens. Directly comparable as a Greek ambulatory diagnostic competitor targeting the same EOPYY-insured patient base.

Regional players

• Medicover: European healthcare and diagnostics provider with strong presence in Central and Eastern Europe. Comparable as a regional diagnostics-and-clinics operator that competes for European ambulatory testing volume outside Alpha Prolipsis's core Athens geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/alphaprolipsis
• Facebookfacebook.com/alphaprolipsis
• LinkedInlinkedin.com/company/alphaprolipsis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALPHA PROLIPSIS